We note that the Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Chief Medical Officer, Narinder Bhalla, recently sold US$99k worth of stock for US$4.42 per share. It might not be a huge sale, but it did reduce their holding size 21%, hardly encouraging.

Lexeo Therapeutics Insider Transactions Over The Last Year

The CEO & Director, R. Townsend, made the biggest insider sale in the last 12 months. That single transaction was for US$117k worth of shares at a price of US$9.56 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$4.69). So it may not tell us anything about how insiders feel about the current share price.

Insiders in Lexeo Therapeutics didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Based on our data, Lexeo Therapeutics insiders have about 0.5% of the stock, worth approximately US$1.8m. I generally like to see higher levels of ownership.

So What Do The Lexeo Therapeutics Insider Transactions Indicate?

Insiders sold Lexeo Therapeutics shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. When you consider that most companies have higher levels of insider ownership, we're a little wary. We'd certainly practice some caution before buying! While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision.

But note: Lexeo Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.